异基因干细胞移植后1年EASIX评分与晚期死亡风险
本研究在训练队列(n=610)和合并验证队列(n=852)中回顾性分析异基因干细胞移植后1年无复发存活患者,评估移植后1年测定的EASIX评分对晚期总生存、非复发死亡和复发风险的预测价值。结果显示EASIX-1year可预测总生存和非复发死亡,但不预测复发风险,且与慢性GVHD发生无显著交互作用。
要点
- 异基因干细胞移植后1年无复发存活者仍面临非复发死亡风险,EASIX-1year可预测晚期总生存和非复发死亡。
- EASIX-1year预测总生存和非复发死亡,但不预测复发风险。
- EASIX-1year与慢性GVHD发生对总生存无显著交互作用。
核心结论
- 据我们所知,EASIX-1year是首个经验证的晚期总生存和非复发死亡的预测指标。
- 作者认为,根据EASIX-1year定义为高风险的患者可考虑加强监测和预防措施。
研究设计与样本
- 回顾性研究,在2个独立队列中进行:训练队列 n=610,合并验证队列 n=852,纳入异基因干细胞移植后1年无复发的存活患者。
- 在训练队列中检测血清内皮和炎症标志物,并与EASIX-1year进行相关性分析。
主要发现
- EASIX-1year与总生存、非复发死亡和复发相关。
- 在训练队列和验证队列的单变量和多变量Cox回归分析中,EASIX-1year预测总生存和非复发死亡,但不预测复发风险。
- Brier评分和c-index分析验证了EASIX的单变量效应。
- EASIX-1year与慢性GVHD发生率对总生存无显著交互作用。
- EASIX-1year预测结局不受既存合并症影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with hematological malignancies who survive the first year after allogeneic stem cell transplantation (allo-SCT) without relapse have a substantial risk of nonrelapse mortality (NRM) and missing predictive markers. The Endothelial Activation and Stress Index (EASIX) predicts endothelial complications and NRM early after allo-SCT. We hypothesized that EASIX assessed 1 year after allo-SCT in survivors who were disease free may predict late NRM. Survivors who were relapse-free at 1 year after allo-SCT were retrospectively studied in 2 independent cohorts (training cohort, n = 610; merged validation cohort, n = 852). EASIX determined 1 year after allo-SCT correlated with the overall survival (OS), NRM, and relapse. Serum endothelial and inflammatory markers were measured in the training cohort and correlated with EASIX-1year, which predicted OS and NRM but not relapse risk in both the training and validation cohorts in univariable and multivariable Cox regression analyses. Brier score and c-index analyses validated the univariable EASIX effects. There was no significant interaction between EASIX-1year and incidence of chronic graft-versus-host disease (GVHD) on OS. EASIX-1year predicted the outcome irrespective of preexisting comorbidities. Principal causes of NRM in both training and validation cohorts were infections with and without GVHD as well as cardiovascular complications. EASIX-1year correlated with sCD141 and interleukin-18 but not with C-reactive protein, suppressor of tumorigenicity-2, angiopoietin-2, CXCL9, or CXCL8. To our knowledge, EASIX-1year is the first validated predictor of late overall and NRM. Patients who are high risk as defined by EASIX-1year might be considered for intensified surveillance and prophylactic measures.
引用
- Kordelas L, Terzer T, Gooley T, et al. EASIX-1year and late mortality after allogeneic stem cell transplantation. Blood Adv. 2023. PMID: 37477588. doi:10.1182/bloodadvances.2022008617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。